Business of Medicine

Teva Canadian MS Community: No Win for the Company

Teva is closing its community forum from its Canadian multiple sclerosis education website because of Canadian healthcare regulations around dissemination of information relating to prescription drugs. You’ll read the explanation if you visit the Teva MS website, but keep reading for the crux of the situation: I have to agree with Teva’s decision because it [...]

Read the full article →

Advil PM v. Tylenol PM Ad is Misleading

This has been bugging me for a long time, but recently I saw another one of these “advil PM versus tylenol PM” commercials, so I am going to finally write about it! First of all, the commercial is basically a “why Advil PM is so much better” ad. It talks about how the person taking [...]

Read the full article →

Top 10 healthcare social media predictions

3 of my predictions appeared here: Industry consultant and entrepreneur Jane Chin (@janechin) goes even further, alleging that next year PhRMA will appoint its first ever ‘Chief Tweeting Officer.’ Jane Chin (@janechin) thinks social media will spur new approaches to customer care and technology, as “cutting edge pharma …companies will experiment with a blend of [...]

Read the full article →

Which Side Are You Really On, Jane Chin?!

I received what is probably the most passionate email from a reader of this blog that I’ve ever gotten since creating NakedMedicine.com in 2006. The email concludes with this: I can’t figure out what your agenda is Ms Chin. Are siding with the poor hard working physicians who are fighting a losing battle with their [...]

Read the full article →

Pharma Offering Lifestyle Drugs – Power will Shift to Patient Customers

You’ve probably seen it coming – smelled hints of it on TV – pharmaceutical companies are getting into what we call “lifestyle drugs”; products that focus on “enhancing” your life rather than “extending” it. Yes, there is a big difference, and you may think that “extending” life pays big, “enhancing” life may pay even BIGGER. [...]

Read the full article →